论文部分内容阅读
目的观察奥扎格雷钠与依达拉奉联合治疗急性脑梗死的临床疗效。方法选取医院2010年5月-2012年5月收治的急性脑梗死患者192例,将其随机分成治疗组和对照组各96例,对照组给予奥扎格雷钠治疗,治疗组在对照组患者治疗的基础上给予依达拉奉联合治疗,比较2组患者的临床疗效、神经功能缺损以及生活能力。结果治疗后,治疗组总有效率为97.9%明显高于对照组的82.3%,差异有统计学意义(P<0.05);治疗组神经功能缺损评分明显低于对照组;生活能力评分明显高于对照组,差异有统计学意义(P<0.05)。结论奥扎格雷钠联合依达拉奉治疗急性脑梗死疗效显著,能够有效改善患者神经功能缺损症状,提高患者预后,值得临床的推广。
Objective To observe the clinical efficacy of sodium ozagrel combined with edaravone in the treatment of acute cerebral infarction. Methods A total of 192 patients with acute cerebral infarction who were admitted from May 2010 to May 2012 in our hospital were randomly divided into treatment group (96 cases) and control group (96 cases), and control group received ozagrel sodium treatment. Patients in the control group Based on the combination of edaravone treatment, the two groups of patients with clinical efficacy, neurological deficits and viability. Results After treatment, the total effective rate of the treatment group was 97.9%, which was significantly higher than that of the control group (82.3%), the difference was statistically significant (P <0.05); the score of neurological deficit in the treatment group was significantly lower than that of the control group; Control group, the difference was statistically significant (P <0.05). Conclusion Ozagrel combined with edaravone has significant therapeutic effect on acute cerebral infarction, which can effectively improve the symptoms of neurological deficits and improve the prognosis of patients, which is worthy of clinical promotion.